A large-scale meta-analysis has identified a reproducible microbial signature associated with colorectal cancer across diverse populations, while a separate review details the molecular mechanisms of these interactions.
A Consistent Microbial Fingerprint for Colorectal Cancer
Researchers from EMBL, LUMC, and collaborators have conducted a landmark meta-analysis of 27 studies, analyzing 6,779 gut microbiome profiles from both CRC patients and healthy controls. The analysis uncovered a microbial signature consistently associated with CRC across different study populations, sequencing methods, and age-of-onset groups.
A machine-learning classifier could reliably distinguish CRC microbiomes from non-cancer microbiomes across various datasets. The study found that the CRC microbiome signature was associated with lower reported dietary fibre intake and was reduced following fibre-focused dietary interventions.
Detection in Tissue and Stool Samples
Analysis of 906 intestinal tissue samples revealed that microbes enriched in tumour tissues were similar to the signature observed in faecal samples. In tissue samples, cancer-associated microbes were detectable in early-stage tumours.
However, detection accuracy in stool samples was lower for early-stage cancers and for tumours located further upstream in the colon.
Pre-cancerous adenomas showed weak and inconsistent microbial changes, indicating limited detectability via stool microbiome profiling.
Bacterial Subspecies and Geographic Variability
The research identified differential enrichment of Fusobacterium subspecies. Specifically, Fusobacterium nucleatum subsp. animalis was consistently enriched in CRC samples across continents. Other subspecies of Fusobacterium exhibited geographic variability in their enrichment patterns.
Methods, Limitations, and Clinical Comparison
The researchers developed computational approaches to integrate microbiome datasets generated using different sequencing methods. The machine-learning algorithm outputs a score indicating how 'cancer-like' a microbiome is, applicable to any gut microbiome dataset.
In comparisons, the microbiome-based classifiers did not match the performance of faecal immunochemical tests (FIT). The authors stated that larger studies are needed to assess potential complementarity with existing clinical tests. The study provides a reference for future microbiome-based detection and risk assessment research.
Molecular Mechanisms of Microbiota-Host Interactions
A separate review, published by researchers from the Institute of Digestive Disease at The Chinese University of Hong Kong in Cancer Biology & Medicine, examined microbiota-host interactions in CRC across four molecular layers: genome, transcriptome, epigenome, and metabolome.
The review highlighted specific bacterial mechanisms:
- Escherichia coli carrying the pks island produces colibactin, a genotoxin that creates a DNA damage signature found in more than 12% of CRC cases.
- Fusobacterium nucleatum uses a protein called FadA to bind to E-cadherin, activating Wnt/β-catenin signaling and cell proliferation.
- Secondary bile acids, such as deoxycholic acid (DCA), suppress cytotoxic CD8+ T cells, which contributes to immune evasion.
Computational Innovations and Emerging Technologies
The review addressed computational challenges in microbiome research, including compositional artifacts, sparsity, and high dimensionality. It noted that machine learning methods (such as random forests and neural networks like MetaNN) help address these issues.
Emerging technologies described include long-read sequencing (PacBio, Oxford Nanopore) and bacterial single-cell spatial transcriptomics (bacterial MERFISH).
Clinical Implications and Future Directions
The review authors stated that the gut microbiome is an active trigger that rewires host biology. They noted that the field has moved from listing bacteria to understanding mechanisms via multi-omics and AI-driven models, and identified the challenge as transitioning from correlation to causation using tools like organ-on-chip systems and gnotobiotic mice.
Potential applications described include:
- Microbiome-based CRC screening
- Prediction of immunotherapy response
- Elimination of specific bacteria (e.g., using phages against enterotoxigenic Bacteroides fragilis)
- Engineering beneficial bacteria for therapeutic delivery
The authors envision "digital twins" integrating patient multi-omics data to forecast effects of dietary changes, prebiotics, or live biotherapeutics.